SSA
ORIC icon

Schonfeld Strategic Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,349
Closed -$117K – 2548
2025
Q4 		$117K Buy
+14,349
New +$165K ﹤0.01% 1795
2025
Q2 		– Sell
-426,902
Closed -$2.38M – 2406
2025
Q1 		$2.38M Sell
426,902
-297,417
-41% -$2.6M 0.01% 876
2024
Q4 		$5.85M Buy
+724,319
New +$6.65M 0.03% 454
2022
Q4 		– Sell
-11,800
Closed -$38K – 2894
2022
Q3 		$38K Sell
11,800
-18,000
-60% -$72.1K ﹤0.01% 2669
2022
Q2 		$133K Buy
29,800
+2,200
+8% +$8.78K ﹤0.01% 2060
2022
Q1 		$148K Buy
+27,600
New +$249K ﹤0.01% 2105

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Schonfeld Strategic Advisors's ORIC Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Oric Pharmaceuticals (ORIC) in Q1 2026, closing a stake of 14,349 shares — an estimated $117K sold.

Schonfeld Strategic Advisors first reported a position in ORIC in Q1 2022 and held it in 6 quarters. The position peaked at $5.85M in Q4 2024. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Oric Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 14,349 Oric Pharmaceuticals shares in Q1 2026, an estimated $117K.
  • Schonfeld Strategic Advisors first reported a position in Oric Pharmaceuticals in Q1 2022 and held it in 6 quarters.
  • Schonfeld Strategic Advisors's Oric Pharmaceuticals position peaked at $5.85M in Q4 2024.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.